Sign in

    Asseema Deng • ODDO BHF

    Asseema Deng is a Director and Equity Analyst at ODDO BHF, specializing in the European healthcare sector, with a particular focus on pharmaceutical and biotechnology companies such as Sanofi, Roche, AstraZeneca, and Novartis. Known for her deep sector expertise, she has consistently delivered investment recommendations that have outperformed sector benchmarks, maintaining a success rate over 60% and strong average portfolio returns according to third-party analytics platforms. Deng began her career in equity research more than a decade ago, holding previous roles at Jefferies and Nomura before joining ODDO BHF in 2020. She holds CFA charterholder status and is registered with relevant European financial regulatory authorities, underscoring her commitment to professional excellence and market integrity.

    Asseema Deng's questions to Innate Pharma SA (IPHA) leadership

    Asseema Deng's questions to Innate Pharma SA (IPHA) leadership • Q1 2025

    Question

    Asseema Deng asked whether the company's current financial visibility and cash runway guidance includes the costs for the planned Phase III trial for lacutamab, and what financing options are being considered.

    Answer

    Jonathan Dickinson, CEO, confirmed that the current cash runway guidance to mid-2026 does not include the cost of the lacutamab Phase III confirmatory study. He stated that the preferred option is to secure a partnership to fund the trial. However, he emphasized that the company will not accept a 'bad deal' and is actively exploring a range of alternative financing options to ensure it can initiate the study, either with a partner or independently if necessary.

    Ask Fintool Equity Research AI